Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Response-adapted Intensification in Newly Diagnosed Multiple Myeloma
NCT01114048Phase 2Unknown
- Sponsor
- Chonnam National University Hospital
- Start
- Mar 2010
- Primary completion
- Mar 2012
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of bortezomib in multiple myeloma (MM) (2 arms), sponsored by Chonnam National University Hospital. Primary endpoint: Overall Response Rate at 2 years. Status: unknown.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01114048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01114048.